((自动化翻译由路透提供，请见免责声明 ))
9月18日 - ** 医疗设备制造商瑞思迈 股价下跌 6.1%，至 235.65 美元
** 券商Wolfe Research将瑞思迈的评级从 "同行表现 "下调至 "表现不佳"，目标价180美元。
* 由于美国食品药品管理局可能在第四季度批准礼来公司 用于睡眠呼吸暂停的减肥药Zepbound (link)，预计明年患者需求将面临重大中断风险 - Wolfe
** 瑞思迈生产持续气道正压机(CPAP) 机--一种有助于控制睡眠呼吸暂停的呼吸机
** 这种疾病导致睡眠时呼吸反复停止或变浅
** 券商援引调查称，由于 Zepbound 等 GLP-1 药物的推出，50% 的医生预计将减少开 CPAP 机治疗睡眠呼吸暂停的处方。
** 该公司股票今年以来的涨幅约为 36%，而标准普尔 500 指数 的涨幅约为 18
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.